RPRX Royalty Pharma Plc

USD 31.95 0.00 ( 0.00%)
Icon

Royalty Pharma Plc (RPRX) Financial Statements

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 31.95

0.00 (0.00%)

USD 19.31B

5.90M

USD 41.29(+29.22%)

N/A

Icon

RPRX

Royalty Pharma Plc (USD)
COMMON STOCK | NSD
USD 31.95
0.00 ( 0.00%)

Royalty Pharma Plc (RPRX) Annual Income Statement (USD)

RPRX Quarterly Financials (USD)

Frequently Asked Questions About Royalty Pharma Plc (RPRX) Stock

Royalty Pharma Plc's (RPRX) last reported annual revenue was USD 2.26 Billion.

Royalty Pharma Plc's (RPRX) annual revenue growth rate based on the revenue reported in the past 5 years is : 4.53%

Royalty Pharma Plc's(RPRX) is profitable as of its last reported annual financials.

The net profit margin for Royalty Pharma Plc's(RPRX) from its laster reported year is 37.94%

The return on equity (ROE) for Royalty Pharma Plc's(RPRX) from its last reported annual financials is : 13.03%

The return on assets (ROA) for Royalty Pharma Plc's(RPRX) from its last reported annual financials is : 4.67%

The return on invested capital (ROIC) for Royalty Pharma Plc's(RPRX) from its last reported annual financials is : 5.36%

The Debt to Equity ratio for Royalty Pharma Plc's(RPRX) from its last reported annual financials is : 63.96%

The dividend yield for Royalty Pharma Plc's(RPRX) from its laster reported year is 2.63%

Royalty Pharma Plc's(RPRX) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...